335 related articles for article (PubMed ID: 14699483)
1. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.
Colombel JF; Loftus EV; Tremaine WJ; Egan LJ; Harmsen WS; Schleck CD; Zinsmeister AR; Sandborn WJ
Gastroenterology; 2004 Jan; 126(1):19-31. PubMed ID: 14699483
[TBL] [Abstract][Full Text] [Related]
2. Safety of infliximab in Crohn's disease: a large single-center experience.
Hamzaoglu H; Cooper J; Alsahli M; Falchuk KR; Peppercorn MA; Farrell RJ
Inflamm Bowel Dis; 2010 Dec; 16(12):2109-16. PubMed ID: 20848473
[TBL] [Abstract][Full Text] [Related]
3. Infliximab for Crohn's disease: the first 500 patients followed up through 2009.
Seminerio JL; Loftus EV; Colombel JF; Thapa P; Sandborn WJ
Dig Dis Sci; 2013 Mar; 58(3):797-806. PubMed ID: 23053885
[TBL] [Abstract][Full Text] [Related]
4. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital.
Seiderer J; Göke B; Ochsenkühn T
Digestion; 2004; 70(1):3-9. PubMed ID: 15297773
[TBL] [Abstract][Full Text] [Related]
5. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
[TBL] [Abstract][Full Text] [Related]
6. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.
Lees CW; Ali AI; Thompson AI; Ho GT; Forsythe RO; Marquez L; Cochrane CJ; Aitken S; Fennell J; Rogers P; Shand AG; Penman ID; Palmer KR; Wilson DC; Arnott ID; Satsangi J
Aliment Pharmacol Ther; 2009 Feb; 29(3):286-97. PubMed ID: 19132970
[TBL] [Abstract][Full Text] [Related]
7. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients.
Ricart E; Panaccione R; Loftus EV; Tremaine WJ; Sandborn WJ
Am J Gastroenterol; 2001 Mar; 96(3):722-9. PubMed ID: 11280541
[TBL] [Abstract][Full Text] [Related]
8. Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up.
Wenzl HH; Reinisch W; Jahnel J; Stockenhuber F; Tilg H; Kirchgatterer A; Petritsch W
Eur J Gastroenterol Hepatol; 2004 Aug; 16(8):767-73. PubMed ID: 15256978
[TBL] [Abstract][Full Text] [Related]
9. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab).
Garcia-Planella E; Domènech E; Esteve-Comas M; Bernal I; Cabré E; Boix J; Gassull MA
Eur J Gastroenterol Hepatol; 2003 Apr; 15(4):351-4. PubMed ID: 12655253
[TBL] [Abstract][Full Text] [Related]
10. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M
Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373
[TBL] [Abstract][Full Text] [Related]
11. Safety of infliximab in 10 years of clinical practice.
O'Donnell S; Murphy S; Anwar MM; O'Sullivan M; Breslin N; O'Connor HJ; Ryan BM; O'Morain CA
Eur J Gastroenterol Hepatol; 2011 Jul; 23(7):603-6. PubMed ID: 21602689
[TBL] [Abstract][Full Text] [Related]
12. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D
Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356
[TBL] [Abstract][Full Text] [Related]
13. Fatal staphylococcal sepsis in Crohn's disease after infliximab.
Herrlinger KR; Borutta A; Meinhardt G; Stange EF; Fellermann K
Inflamm Bowel Dis; 2004 Sep; 10(5):655-6. PubMed ID: 15472530
[TBL] [Abstract][Full Text] [Related]
14. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort.
de Ridder L; Rings EH; Damen GM; Kneepkens CM; Schweizer JJ; Kokke FT; Benninga MA; Norbruis OF; Hoekstra JH; Gijsbers CF; Escher JC
Inflamm Bowel Dis; 2008 Mar; 14(3):353-8. PubMed ID: 18069674
[TBL] [Abstract][Full Text] [Related]
15. Review article: safety of infliximab in clinical trials.
Hanauer SB
Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():16-22; discussion 38. PubMed ID: 10597335
[TBL] [Abstract][Full Text] [Related]
16. The incidence and management of infusion reactions to infliximab: a large center experience.
Cheifetz A; Smedley M; Martin S; Reiter M; Leone G; Mayer L; Plevy S
Am J Gastroenterol; 2003 Jun; 98(6):1315-24. PubMed ID: 12818276
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease.
Lamireau T; Cézard JP; Dabadie A; Goulet O; Lachaux A; Turck D; Maurage C; Morali A; Sokal E; Belli D; Stoller J; Cadranel S; Ginies JL; Viola S; Huet F; Languepin J; Lenaerts C; Bury F; Sarles J;
Inflamm Bowel Dis; 2004 Nov; 10(6):745-50. PubMed ID: 15626892
[TBL] [Abstract][Full Text] [Related]
19. How to improve the safety of biologic therapy in Crohn's disease.
Ferkolj I
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
Cohen RD
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S17-22. PubMed ID: 11380038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
